Hoe verhoudt 3933's PE Ratio zich tot zijn concurrenten?

3933 is een goede waarde op basis van zijn Price-To-Earnings Ratio (5.9x) vergeleken met het gemiddelde van gelijken (8.8x).

Hoe verhoudt 3933's PE Ratio zich tot andere bedrijven in de HK Pharmaceuticals industrie?

3933 is een goede waarde op basis van de Price-To-Earnings -ratio ( 5.9 x) vergeleken met het Hong Kong Pharmaceuticals -industriegemiddelde ( 8.4 x).

Wat is 3933's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

3933 is een goede waarde op basis van de Price-To-Earnings -ratio ( 5.9 x) vergeleken met de geschatte eerlijke Price-To-Earnings -ratio ( 10.6 x).

Wat is de reële prijs van 3933 als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

3933 ( HK$10.16 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( HK$45.99 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is minder dan 20 % hoger dan de huidige aandelenkoers.

United Laboratories International Holdings (SEHK:3933) - Aandelenkoers, Nieuws & Analyse

3933 Overzicht aandelen

3933 fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	1/6
Prestaties in het verleden	5/6
Financiële gezondheid	6/6
Dividenden	3/6

Beloningen

Verhandeld tegen 77.9% onder onze schatting van de reële waarde

De winst zal naar verwachting met 3.88% per jaar groeien

De winst groeide het afgelopen jaar met 30.1%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Onstabiel dividend track record

The United Laboratories International Holdings Limited Concurrenten

Grand Pharmaceutical Group

SEHK:512

HK$15.6b

China Medical System Holdings

SEHK:867

HK$18.5b

SSY Group

SEHK:2005

HK$11.3b

China Resources Pharmaceutical Group

SEHK:3320

HK$33.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor United Laboratories International Holdings
Historische aandelenkoersen
Huidige aandelenkoers	HK$10.16
52 Week Hoogtepunt	HK$11.74
52 Week Laag	HK$6.52
Bèta	0.058
11 maand verandering	-5.93%
3 maanden verandering	20.52%
1 Jaar Verandering	28.44%
33 jaar verandering	84.73%
5 jaar verandering	109.05%
Verandering sinds IPO	181.44%

Recent nieuws en updates

These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely

Nov 11

The United Laboratories International Holdings Limited (HKG:3933) Stock Catapults 29% Though Its Price And Business Still Lag The Market

Oct 23

Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching

Aug 30

Recent updates

These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely

Nov 11

The United Laboratories International Holdings Limited (HKG:3933) Stock Catapults 29% Though Its Price And Business Still Lag The Market

Oct 23

Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching

Aug 30

Improved Earnings Required Before The United Laboratories International Holdings Limited (HKG:3933) Stock's 26% Jump Looks Justified

Feb 29

The United Laboratories International Holdings Limited's (HKG:3933) Low P/E No Reason For Excitement

Jan 04

United Laboratories International Holdings (HKG:3933) Could Easily Take On More Debt

Dec 14

With EPS Growth And More, United Laboratories International Holdings (HKG:3933) Makes An Interesting Case

Nov 26

Is United Laboratories International Holdings (HKG:3933) A Risky Investment?

Aug 31

Does United Laboratories International Holdings (HKG:3933) Deserve A Spot On Your Watchlist?

Aug 10

United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet

Dec 23

Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?

Oct 19

Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?

Aug 30

Is The United Laboratories International Holdings Limited (HKG:3933) A Smart Pick For Income Investors?

Mar 08

The United Laboratories International Holdings (HKG:3933) Share Price Is Up 108% And Shareholders Are Boasting About It

Feb 18

The United Laboratories International Holdings Limited's (HKG:3933) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 03

Did The United Laboratories International Holdings Limited (HKG:3933) Insiders Sell Shares?

Jan 19

We Wouldn't Rely On United Laboratories International Holdings's (HKG:3933) Statutory Earnings As A Guide

Jan 04

These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely

Dec 20

What Type Of Shareholders Own The Most Number of The United Laboratories International Holdings Limited (HKG:3933) Shares?

Dec 07

The United Laboratories International Holdings Limited (HKG:3933) Is Yielding 1.3% - But Is It A Buy?

Nov 23

Rendement voor aandeelhouders

	3933	HK Pharmaceuticals	HK Markt
7D	0.4%	0.8%	0.4%
1Y	28.4%	-7.5%	12.0%

Rendement versus industrie: 3933 overtrof de Hong Kong Pharmaceuticals industrie, die het afgelopen jaar een rendement -7.5 % opleverde.

Rendement versus markt: 3933 overtrof de Hong Kong markt, die het afgelopen jaar een rendement opleverde van 12 %.

Prijsvolatiliteit

Is 3933's price volatile compared to industry and market?
3933 volatility
3933 Average Weekly Movement	6.1%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

Stabiele aandelenkoers: 3933 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van 3933 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1990	15,000	n/a	www.tul.com.cn

United Laboratories International Holdings Limited, een beleggingsholding, houdt zich bezig met onderzoek en ontwikkeling, productie, distributie en verkoop van farmaceutische producten. Het is actief in drie segmenten: Bulkgeneesmiddelen, Tussenproducten en Eindproducten. Het bedrijf biedt orale antibiotica, antimicrobiële middelen voor injectie, antikoudheidsproducten, hoestmedicijnen, oogheelkundige geneesmiddelen, antivirale geneesmiddelen, geneesmiddelen tegen hepatitis B, diabetesmedicijnen, huidmedicijnen voor uitwendig gebruik, cardiovasculaire en cerebrovasculaire geneesmiddelen, amoxicillineproducten, geneesmiddelen voor het zenuwstelsel, vitaminen, diergeneesmiddelen en vrije gelatinecapsules.

The United Laboratories International Holdings Limited Samenvatting

Hoe verhouden de winst en inkomsten van United Laboratories International Holdings zich tot de beurswaarde?
3933 fundamentele statistieken
Marktkapitalisatie	HK$18.46b
Inkomsten(TTM)	HK$3.13b
Inkomsten(TTM)	HK$15.06b

5.9x

Koers/Winstverhouding

1.2x

P/S-verhouding

Is 3933 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
3933 resultatenrekening (TTM)
Inkomsten	CN¥14.01b
Kosten van inkomsten	CN¥7.54b
Brutowinst	CN¥6.47b
Overige uitgaven	CN¥3.56b
Inkomsten	CN¥2.91b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	1.60
Brutomarge	46.15%
Nettowinstmarge	20.76%
Schuld/Eigen Vermogen Verhouding	18.0%

Hoe presteerde 3933 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

5.9%

Huidig dividendrendement

27%

Uitbetalingsratio

3933 Overzicht aandelen

Beloningen

Risicoanalyse

The United Laboratories International Holdings Limited Concurrenten

SEHK:512

HK$15.6b

SEHK:867

HK$18.5b

SEHK:2005

HK$11.3b

SEHK:3320

HK$33.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely

The United Laboratories International Holdings Limited (HKG:3933) Stock Catapults 29% Though Its Price And Business Still Lag The Market

The United Laboratories International Holdings Limited Announces the Application for Marketing of Insulin Degludec Injection

First half 2024 earnings: EPS exceeds analyst expectations

Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching

The United Laboratories International Holdings Limited Declares Interim Dividend for the Six Months Ended 30 June 2024

Recent updates

These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely

The United Laboratories International Holdings Limited (HKG:3933) Stock Catapults 29% Though Its Price And Business Still Lag The Market

The United Laboratories International Holdings Limited Announces the Application for Marketing of Insulin Degludec Injection

First half 2024 earnings: EPS exceeds analyst expectations

Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching

The United Laboratories International Holdings Limited Declares Interim Dividend for the Six Months Ended 30 June 2024

The United Laboratories International Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 16%

The United Laboratories International Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Improved Earnings Required Before The United Laboratories International Holdings Limited (HKG:3933) Stock's 26% Jump Looks Justified

The United Laboratories International Holdings Limited's (HKG:3933) Low P/E No Reason For Excitement

United Laboratories International Holdings (HKG:3933) Could Easily Take On More Debt

With EPS Growth And More, United Laboratories International Holdings (HKG:3933) Makes An Interesting Case

New minor risk - Share price stability

Price target increased by 18% to HK$10.66

Price target increased by 8.4% to HK$9.06

The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection

the United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023

Investor sentiment deteriorates as stock falls 17%

Price target increased by 12% to HK$8.36

The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

the United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023

Is United Laboratories International Holdings (HKG:3933) A Risky Investment?

New major risk - Revenue and earnings growth

The United Laboratories International Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment improves as stock rises 17%

Does United Laboratories International Holdings (HKG:3933) Deserve A Spot On Your Watchlist?

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 7.4% to HK$5.85

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to HK$5.42

United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet

Investor sentiment improved over the past week

Less than half of directors are independent

Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?

The United Laboratories International Holdings Limited Announces Approval of Marketing of Sodium Hyaluronate Eye Drops Applied by Zhuhai United Laboratories Co., Ltd

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 181,757,450 shares, representing 10% of its issued share capital, under the authorization approved on June 21, 2022.

The United Laboratories International Holdings Limited Announces an Interim Dividend for the Year 2022, Payable on 6 October 2022

Price target decreased to HK$5.02

The United Laboratories International Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2022

First half 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.34 in 1H 2021)

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2021, Payable on 20 July 2022

The United Laboratories International Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Price target decreased to HK$5.54

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to HK$6.38

Less than half of directors are independent

Investor sentiment improved over the past week

Price target decreased to HK$7.34

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 184,039,050 shares, representing 10% of its issued share capital, under the authorization approved on June 22, 2021.

Investor sentiment deteriorated over the past week

Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?

First half 2021 earnings released: EPS CN¥0.34 (vs CN¥0.12 in 1H 2020)